Next |
home / stock / icpt / icpt message board
Subject | By | Source | When |
---|---|---|---|
Good read | Phoenix300 | investorshub | 05/20/2023 1:24:29 AM |
Did you type what you meant? Ocaliva has | DewDiligence | investorshub | 05/19/2023 10:21:16 PM |
Ocaliva is the classic example of a drug | sunspotter | investorshub | 05/19/2023 10:10:05 PM |
FDA advisory panel votes 15-1 against accelerated approval for Ocaliva in | DewDiligence | investorshub | 05/19/2023 9:38:20 PM |
is it bear time? Or do we go bull? | DewDiligence | investorshub | 05/19/2023 5:45:10 AM |
Price gaining | makinezmoney | investorshub | 05/17/2023 9:34:28 AM |
The gaining last up | DewDiligence | investorshub | 05/16/2023 2:17:50 AM |
$ICPT Long and strong lets hope im right | OverDraught | investorshub | 05/14/2023 3:37:23 AM |
Have a look at this | DewDiligence | investorshub | 05/13/2023 8:22:06 PM |
MomentumIts trading up | harry crumb | investorshub | 05/13/2023 9:18:16 AM |
$ICPT bulls and bears | Zilla | investorshub | 05/12/2023 12:09:22 AM |
$ICPT got some short data | DewDiligence | investorshub | 05/11/2023 9:55:59 AM |
$ICPT Price gaining up | harry crumb | investorshub | 05/11/2023 9:24:12 AM |
short data if anyone is interested | DewDiligence | investorshub | 05/09/2023 2:30:12 PM |
MomentumIts trading last up | whytestocks | investorshub | 05/07/2023 5:22:18 PM |
$ICPT Price trading | kingsransome | investorshub | 05/03/2023 4:54:31 PM |
$ICPT short squeeze all day | crudeoil24 | investorshub | 05/02/2023 8:16:23 PM |
$ICPT Anyone hear anything lately? Want to see this one go | sunspotter | investorshub | 05/01/2023 6:26:50 AM |
$ICPT short squeeze all day | Patrickwan1 | investorshub | 04/30/2023 8:50:39 AM |
$ICPT MomentumIts now last trade up | whytestocks | investorshub | 04/28/2023 6:52:01 AM |
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...